Sellers drying up?, page-23

Just asking the obvious here. Leave aside what GK said in the past, but if Dr Stehn was of the opinion in 2014 that Anisina was sufficiently mature to head into clinic by mid 2015, then the question is what held it up? There was nothing to suggest any problems/difficulties encountered with Anisina that I can recall.
I know things always take more time than expected, but it would be really nice to have an NRT drug going through clinical trial right now.